Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Company Overview

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biopharmaceutical company developing orally administered small-molecule drugs for inflammatory, metabolic, liver and cancer-related diseases. The company’s research is based primarily on compounds that target the A3 adenosine receptor, a receptor believed to play a role in regulating immune and inflammatory responses.

Can-Fite’s lead candidates include piclidenoson, also known as CF101, which has been studied for conditions such as rheumatoid arthritis and psoriasis, and namodenoson, also known as CF102, which is being developed for liver-related diseases including metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma. The company has also investigated additional applications for its A3 adenosine receptor platform, including potential treatments for other inflammatory, oncological and metabolic disorders.

Founded in 1994, Can-Fite conducts research and clinical development activities in Israel and internationally, including through studies involving patients and regulatory interactions in the United States and other markets. The company was founded by Dr. Pnina Fishman, who has served as its chief executive officer and has been associated with the development of its A3 adenosine receptor-based platform. Can-Fite’s products remain in clinical development and are not broadly marketed as approved commercial therapies.

Key Stats

• Today's Range: $2.15 to $2.18
• 50-Day Range: $2.16 to $3.58
• 52-Week Range: $2.15 to $12.80
• Volume: 14,298 shs
• Average Volume: 1.01 million shs
• Market Capitalization: $2.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Moderate Buy

Can-Fite BioPharma Stock Analysis - MarketRank™

Can-Fite BioPharma scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Can-Fite BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Can-Fite BioPharma has a consensus price target of $44.00, representing about 1,937.0% upside from its current price of $2.16.

Amount of Analyst Coverage

Can-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Can-Fite BioPharma is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Can-Fite BioPharma is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Can-Fite BioPharma has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CANF.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Can-Fite BioPharma does not currently pay a dividend.

Dividend Growth

Can-Fite BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Can-Fite BioPharma this week, compared to 1 article on an average week.

Search Interest

5 people have searched for CANF on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Can-Fite BioPharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.80% of the stock of Can-Fite BioPharma is held by insiders.

Percentage Held by Institutions

21.00% of the stock of Can-Fite BioPharma is held by institutions.

Company Calendar

• Last Earnings: 11/30/2021
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:CANF
• CIK: 1536196
• Web: www.canfite.com
• Phone: 972-3-924-1114
• Fax: 972-3924-9378
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Can-Fite BioPharma: $44.00
• High Price Target: $80.00
• Low Price Target: $8.00
• Potential Upside/Downside: +1,927.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $405 thousand
• Price / Sales: 5.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 1.23

Miscellaneous

• Outstanding Shares: 1,070,000
• Free Float: N/A
• Market Cap: $2.32 million
• Optionable: Not Optionable
• Beta: 1.12